Support Psychedelic Science to Help Change Lives

MAPS is a leader in psychedelic research. Since 1986, MAPS is on a mission to create safe and legal opportunities for the uses of psychedelics in society.

Choose an amount to give

GIVE ONCE MONTHLY

$

USD/mo

Your donation qualifies you to receive the MAPS Bulletin by mail.

Receive a printed copy of the MAPS Bulletin

Together, we can cross the finish line and make MDMA a medicine

Early next year, MAPS will publish the full results of our first of two Phase 3 clinical trials for MDMA-assisted therapy for PTSD. Phase 3 is the final stage before seeking FDA approval for a new prescription treatment.

If successful, this treatment could transform the lives of millions of people who live with the impacts of complex trauma.

Nature Medicine Journal Publication: MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

We’re in the midst of a global renaissance of psychedelic research

"Psychedelics, when used wisely, have the potential to heal us, help inspire us, and perhaps even save us."

—Rick Doblin, Ph.D., MAPS Founder and Executive Director

Watch MAPS Founder Rick Doblin, Ph.D. present the first TED Talk on psychedelics to an audience in Vancouver, British Columbia.

Help us usher in a new paradigm of mental health

“The work we’re doing at MAPS PBC is related to making MDMA-assisted therapy available as a prescription treatment and the mission of MAPS is to do this with total transparency, open science, and putting public benefit first.”

—Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC)

On the June 4, 2021, MAPS Founder and Executive Director Rick Doblin, Ph.D., appeared on an episode of The Joe Rogan Experience, the most popular podcast in the world.

In the May 4, 2021, edition of The New York Times newspaper, the world-renowned publication reveals research results from the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).

Become a Psychedelic Advocate

Monthly MAPS donors sustain our work and support year-round psychedelic research, drug policy reform, public education, harm reduction, peer support, and general operations.

World-renowned visionary artist Alex Grey has honored MAPS by painting Psychedelic Healing, a uniquely psychedelic rendition of the MAPS logo! To celebrate MAPS' 35th anniversary, the Chapel of Sacred Mirrors (CoSM) is selling a limited series of 350 fine art prints signed by Alex Grey and MAPS Founder Rick Doblin, Ph.D.

Press Releases

MAPS to Receive $1.5 Million to Evaluate Collaboration with Wesana Health in TBI Treatment

September 14, 2021

MAPS Awarded $12.9 Million Grant from Michigan to Expand Cannabis Research for Veterans with PTSD

August 10, 2021

U.S. House Appropriations Bill Signals Sea Change in Psychedelic, Cannabis Research

July 30, 2021

MAPS News

Our 35th Anniversary, New Logo, and New Video

Now Hiring - Explore Career Opportunities

MAPS Newsletter: September 2021

The MAPS Bulletin: The Emergent Psychedelic Ecosystem is now available online!

Featured Media

The New York Times:
A Psychedelic Drug Passes Big Test for PTSD Treatment

The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

The Washington Post:
Who Will Benefit From Psychedelic Medicine?

Boston Magazine:
The Interview: MDMA-Therapy Expert Dr. Rick Doblin

MDMA-assisted therapy is the only treatment for PTSD designated by the FDA as a breakthrough therapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist therapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored clinical trials of MDMA-assisted therapy for anxiety associated with life-threatening illness and social anxiety in autistic adults, LSD-assisted therapy for anxiety, and medical marijuana for PTSD in veterans of war. We have sponsored observational studies for ibogaine therapy for drug addiction and ayahuasca-assisted treatment for drug addiction and PTSD.

Our Education Programs

In addition to our clinical research programs, MAPS provides harm reduction training and services through the Zendo Project, advocates for reducing barriers to scientific research with psychedelics and marijuana, and curates educational events and webinars.

Our Values

Integrity

Information is shared transparently. Communications are respectful, honest, and forthright, and our decisions are informed by compassion and research.

Perseverance

We mindfully persist in the face of challenges, and we build with a balanced, long-term vision.

Curiosity

We are always open to new possibilities: we try new things, take risks, and learn from our mistakes.

Equity

We work for ethical and equitable access for all.

MAPS

We are a 501(c)(3) non-profit research and educational organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Watch videos from Psychedelic Science 2017.

Media

September 18, 2021 NBC News: California Moves Closer to Decriminalizing Psychedelic Drugs
September 17, 2021 AJMC: Could Psychedelics Ease Mental Health Toll From COVID-19, Other Crises?
September 14, 2021 MAPS to Receive $1.5 Million to Evaluate Collaboration with Wesana Health in TBI Treatment

About Us

Contact Us

3141 Stevens Creek Blvd #40563
San Jose, CA 95117
Phone: 831-429-MDMA (6362)
Fax: 831-429-6370
Ask MAPS
Media Requests

Log in to your account